Desmorpholinyl navitoclax-NH-Me
Based on 1 Customer Validation
Desmorpholinyl navitoclax-NH-Me (Desmorpholinyl ABT-263-NH-Me) is an N-methylamino-substituted derivative of Navitoclax (HY-10087) and a BCL-XL-targeting PROTAC precursor. Desmorpholinyl navitoclax-NH-Me is used for the synthesis of BCL-XL-targeting PROTACs and related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.64%
- CAS No.: 2365172-82-1
- Formule: C44H51ClF3N5O5S3
- Masse moléculaire:918.55
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-19741
A-1331852Bcl-xL Inhibitor -
HY-15607A
WEHI-539 hydrochlorideBcl-XL Inhibitor -
HY-10087
NavitoclaxBcl-2 Inhibitor -
HY-100741
S63845MCL1 Inhibitor -
HY-18628
UMI-77Bcl-2 Family Inhibitor -
HY-10087R
Navitoclax (Standard)Reference Standard -
HY-10969
Obatoclax MesylateBcl-2 Family Inhibitor -
HY-117288
S55746Bcl-2 Inhibitor -
HY-112218
MIK665MCL1 Inhibitor -
HY-125876
PROTAC Bcl2 degrader-1PROTAC Bcl-2 Degrader -
HY-12020
TW-37Bcl-2 Family Inhibitor -
HY-138832
BM-1244Bcl-xL/Bcl-2 Inhibitor
Activité biologique
Description
IC50 & Target
[1]|
Bcl-xL |
In Vitro
Desmorpholinyl navitoclax-NH-Me (Desmorpholinyl ABT-263-NH-Me) (compound 19) is obtained by deprotection of compound 27, affording a 60% yield after purification.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
CAS No. 2365172-82-1
-
Appearance Solid
-
Masse moléculaire 918.55
-
Formule C44H51ClF3N5O5S3
-
Color White to off-white
-
SMILES
O=C(C1=CC=C(N2CCN(CC3=C(C4=CC=C(Cl)C=C4)CCC(C)(C)C3)CC2)C=C1)NS(C5=CC(S(=O)(C(F)(F)F)=O)=C(N[C@@H](CSC6=CC=CC=C6)CCNC)C=C5)(=O)=O
-
Synonyms
Desmorpholinyl ABT-263-NH-Me
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (108.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (2.72 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (2.72 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0887 mL | 5.4434 mL | 10.8867 mL | 27.2168 mL |
| 5 mM | 0.2177 mL | 1.0887 mL | 2.1773 mL | 5.4434 mL | |
| 10 mM | 0.1089 mL | 0.5443 mL | 1.0887 mL | 2.7217 mL | |
| 15 mM | 0.0726 mL | 0.3629 mL | 0.7258 mL | 1.8145 mL | |
| 20 mM | 0.0544 mL | 0.2722 mL | 0.5443 mL | 1.3608 mL | |
| 25 mM | 0.0435 mL | 0.2177 mL | 0.4355 mL | 1.0887 mL | |
| 30 mM | 0.0363 mL | 0.1814 mL | 0.3629 mL | 0.9072 mL | |
| 40 mM | 0.0272 mL | 0.1361 mL | 0.2722 mL | 0.6804 mL | |
| 50 mM | 0.0218 mL | 0.1089 mL | 0.2177 mL | 0.5443 mL | |
| 60 mM | 0.0181 mL | 0.0907 mL | 0.1814 mL | 0.4536 mL | |
| 80 mM | 0.0136 mL | 0.0680 mL | 0.1361 mL | 0.3402 mL | |
| 100 mM | 0.0109 mL | 0.0544 mL | 0.1089 mL | 0.2722 mL |
Desmorpholinyl navitoclax-NH-Me Related Classifications
HY-131232 Related Classifications
Powered by Bioz
Keywords
- Desmorpholinyl navitoclax-NH-Me
- 2365172-82-1
- Desmorpholinyl ABT-263-NH-Me
- Bcl-2 Family
- Ligands for Target Protein for PROTAC
- low platelet toxicity
- T-cell acute lymphoblastic leukemia
- caspase-dependent apoptosis inducer
- proteasome- and CRBN-dependent BCL-XL degradation
- MOLT-4 viability
- BCL-XL degradation
- BCL-XL PROTAC degrader
- Inhibitor
- inhibitor
- inhibit